Kardigan, Inc. (KARD)Healthcare | Biotechnology | Princeton, United States | NasdaqGM
20.02 USD
-0.78
(-3.750%) ⇩
(Aug. 28, 2026, 4 p.m.
EDT)
After hours: 20.41 +0.39 (1.948%) ⇧ (Aug. 28, 2026, 7:42 p.m. EDT) |
Hot Take ↕ | Aug. 22, 2026, 1:46 a.m. EDT
The immediate outlook is neutral due to a lack of statistical data to confirm short-term momentum, despite the stock trading near its 52-week lows. However, the long-term picture is fundamentally broken: the company is a biotech firm with negative earnings, negative book value, and negative operating cash flow, meaning it is burning cash without generating profit. While analysts project a significant upside to $43.50, this is based on potential future success rather than current financial reality. Crucially, the company has no history of paying dividends, offering zero income to investors. The recent news of an IPO suggests the company is still establishing itself in public markets, which inherently carries high execution risk and volatility, making it unsuitable for capital preservation or income generation at this stage. |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.168 |
| Market Cap | 1,871,944,064 |
| Forward P/E | -6.26 |
| Website | https://www.kardigan.bio |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.089999974 |
| Address1 | 506 Carnegie Center Drive |
| Address2 | Suite 201 |
| All Time High | 27.0 |
| All Time Low | 16.25 |
| Ask | 21.4 |
| Ask Size | 1 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 251,150 |
| Average Daily Volume3 Month | 461,236 |
| Average Volume | 461,236 |
| Average Volume10Days | 251,150 |
| Bid | 20.94 |
| Bid Size | 1 |
| Book Value | 6.585 |
| City | Princeton |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 20.02 |
| Current Ratio | 8.716 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,786,665,600 |
| Day High | 20.925 |
| Day Low | 19.99 |
| Debt To Equity | 2.168 |
| Display Name | Kardigan |
| Earnings Timestamp | 1,786,451,400 |
| Earnings Timestamp End | 1,794,227,400 |
| Earnings Timestamp Start | 1,794,227,400 |
| Ebitda | -265,676,992 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.847 |
| Enterprise Value | 1,287,696,000 |
| Eps Current Year | -4.54391 |
| Eps Forward | -3.19927 |
| Eps Trailing Twelve Months | -2.98 |
| Esg Populated | 0 |
| Exchange | NGM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 21.8384 |
| Fifty Day Average Change | -1.8183994 |
| Fifty Day Average Change Percent | -0.08326615 |
| Fifty Two Week Change Percent | -8.999997 |
| Fifty Two Week High | 27.0 |
| Fifty Two Week High Change | -6.9799995 |
| Fifty Two Week High Change Percent | -0.2585185 |
| Fifty Two Week Low | 16.25 |
| Fifty Two Week Low Change | 3.7700005 |
| Fifty Two Week Low Change Percent | 0.23200002 |
| Fifty Two Week Range | 16.25 - 27.0 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,781,789,400,000 |
| Float Shares | 51,758,973 |
| Forward Eps | -3.19927 |
| Forward P E | -6.2576776 |
| Full Exchange Name | NasdaqGM |
| Full Time Employees | 241 |
| Fullday Change | -0.779999 |
| Fullday Change Percent | -3.74999 |
| Fullday Price | 20.41 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.33516997 |
| Held Percent Institutions | 0.77591 |
| Implied Shares Outstanding | 93,503,699 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,026-06-18 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Kardigan, Inc. operates as a biopharmaceutical company focused on developing medicines for cardiovascular diseases. The company develops and provides a portfolio of medicines that target the underlying pathophysiology of cardiovascular diseases, including primary and secondary cardiomyopathies leading to heart failure. It utilizes a proprietary research and development platform that integrates AI-based tools, real-world clinical data, and cardiac-specific analytics to optimize clinical study design, patient screening, and efficacy tracking. The company incorporates Prolaio's cardiovascular data collection and analytics platform, which includes FDA-cleared algorithms and high-density patient data, to support drug development and clinical intelligence. The company engages in strategic in-licensing and acquisitions to expand its pipeline of targeted treatments. Kardigan serves biopharmaceutical companies, cardiovascular researchers, and healthcare providers in the cardiology sector. The company was formerly known as EnCarda, Inc. and changed its name to Kardigan, Inc. in December 2024. The company was founded in 2023 and is based in Princeton, New Jersey. |
| Long Name | Kardigan, Inc. |
| Market | us_market |
| Market Cap | 1,871,944,064 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_1916374431 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -288,784,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 1,943,006,865 |
| Number Of Analyst Opinions | 4 |
| Open | 20.61 |
| Operating Cashflow | -205,608,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | (415) 573-3220 |
| Post Market Change | 0.3899994 |
| Post Market Change Percent | 1.9480488 |
| Post Market Price | 20.41 |
| Post Market Time | 1,787,960,534 |
| Previous Close | 20.8 |
| Price Eps Current Year | -4.405897 |
| Price Hint | 2 |
| Price To Book | 3.040243 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.537 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.25 |
| Region | US |
| Regular Market Change | -0.779999 |
| Regular Market Change Percent | -3.74999 |
| Regular Market Day High | 20.925 |
| Regular Market Day Low | 19.99 |
| Regular Market Day Range | 19.99 - 20.925 |
| Regular Market Open | 20.61 |
| Regular Market Previous Close | 20.8 |
| Regular Market Price | 20.02 |
| Regular Market Time | 1,787,947,201 |
| Regular Market Volume | 196,555 |
| Sand P52 Week Change | 0.20204377 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 93,503,699 |
| Shares Percent Shares Out | 0.0207 |
| Shares Short | 1,937,583 |
| Shares Short Previous Month Date | 1,784,073,600 |
| Shares Short Prior Month | 1,670,728 |
| Short Name | Kardigan, Inc. |
| Short Percent Of Float | 0.024300002 |
| Short Ratio | 8.3 |
| Source Interval | 15 |
| State | NJ |
| Symbol | KARD |
| Target High Price | 46.0 |
| Target Low Price | 37.0 |
| Target Mean Price | 42.25 |
| Target Median Price | 43.0 |
| Total Cash | 597,595,008 |
| Total Cash Per Share | 6.391 |
| Total Debt | 13,347,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -2.98 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 21.8384 |
| Two Hundred Day Average Change | -1.8183994 |
| Two Hundred Day Average Change Percent | -0.08326615 |
| Type Disp | Equity |
| Volume | 196,555 |
| Website | https://www.kardigan.bio |
| Zip | 8,540 |